93 related articles for article (PubMed ID: 12661333)
1. [Reproducibility of Her-2/neu overexpression with HERCEP test in invasive ductal breast cancer].
Rodríguez Moguel L; Vega Ramos B
Ginecol Obstet Mex; 2002 Dec; 70():601-6. PubMed ID: 12661333
[TBL] [Abstract][Full Text] [Related]
2. High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study.
Lacroix-Triki M; Mathoulin-Pelissier S; Ghnassia JP; Macgrogan G; Vincent-Salomon A; Brouste V; Mathieu MC; Roger P; Bibeau F; Jacquemier J; Penault-Llorca F; Arnould L
Eur J Cancer; 2006 Nov; 42(17):2946-53. PubMed ID: 16989997
[TBL] [Abstract][Full Text] [Related]
3. Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest.
Hsu CY; Ho DM; Yang CF; Lai CR; Yu IT; Chiang H
Am J Clin Pathol; 2002 Nov; 118(5):693-8. PubMed ID: 12428788
[TBL] [Abstract][Full Text] [Related]
4. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer.
Ivkovic-Kapicl T; Knezevic-Usaj S; Djilas-Ivanovic D; Panjkovic M
In Vivo; 2007; 21(4):673-8. PubMed ID: 17708365
[TBL] [Abstract][Full Text] [Related]
5. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
[TBL] [Abstract][Full Text] [Related]
6. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma.
Cho MH; Yoon JH; Jaegal YJ; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Lee MC; Park CS; Woo Juhng S; Min KW
Breast; 2006 Jun; 15(3):390-8. PubMed ID: 16169726
[TBL] [Abstract][Full Text] [Related]
7. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
8. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
9. A two-phase study model for the standardization of HER2 immunohistochemical assay on invasive ductal carcinoma of the breast.
Sampatanukul P; Chaiwun B; Wongwaisayawan S; Suwanagool P; Vinyuvat S; Karalak A; Praditphol N; Paueksakon P; Ruangvejvorachai P; Field AS; Wannakrairot P
J Med Assoc Thai; 2005 Nov; 88(11):1680-8. PubMed ID: 16471119
[TBL] [Abstract][Full Text] [Related]
10. Does thymidine phosphorylase correlate with angiogenesis in intraductal carcinoma of the breast?
Erkus M; Meteoglu I; Culhaci N; Meydan N; Erdogdu I
Saudi Med J; 2006 Sep; 27(9):1329-33. PubMed ID: 16951768
[TBL] [Abstract][Full Text] [Related]
11. Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas.
Falo C; Moreno A; Lloveras B; Figueras A; Varela M; Escobedo A
Am J Clin Oncol; 2003 Oct; 26(5):465-70. PubMed ID: 14528071
[TBL] [Abstract][Full Text] [Related]
12. Her-2/neu expression in breast cancer--A comparison of different diagnostic methods.
Benöhr P; Henkel V; Speer R; Vogel U; Sotlar K; Aydeniz B; Reiser A; Neubauer H; Tabiti K; Wallwiener D; Clare SE; Kurek R
Anticancer Res; 2005; 25(3B):1895-900. PubMed ID: 16158923
[TBL] [Abstract][Full Text] [Related]
13. Her2/neu analysis in formalin-fixed, paraffin-embedded breast carcinomas: comparison of immunohistochemistry and multiparameter DNA flow cytometry.
Leers MP; Hoop JG; Nap M
Anticancer Res; 2003; 23(2A):999-1006. PubMed ID: 12820338
[TBL] [Abstract][Full Text] [Related]
14. Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy.
Bloom K; Harrington D
Am J Clin Pathol; 2004 May; 121(5):620-30. PubMed ID: 15151201
[TBL] [Abstract][Full Text] [Related]
15. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
[TBL] [Abstract][Full Text] [Related]
16. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical evaluation of HER-2/neu expression in infiltrating breast carcinoma: a study of reproducibility.
Santinelli A; Baccarini M; Colanzi P; Stramazzotti D; Fabris G
Anal Quant Cytol Histol; 2002 Feb; 24(1):54-62. PubMed ID: 11865950
[TBL] [Abstract][Full Text] [Related]
18. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
19. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.
Dolan M; Snover D
Am J Clin Pathol; 2005 May; 123(5):766-70. PubMed ID: 15981817
[TBL] [Abstract][Full Text] [Related]
20. [Interobserver reproducibility in the pathologic diagnosis of borderline ductal proliferative breast diseases].
Wei B; Bu H; Zhu CR; Guo LX; Chen HJ; Zhao C; Zhang P; Chen DY; Tang Y; Jiang Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):849-53. PubMed ID: 15573772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
